GILD241011C89000
- 0.08
- +0.04+100.00%
Gilead Sciences Newsroom
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Gilead Sciences Is Maintained at Equal-Weight by Barclays
Express News | Gilead Sciences Inc - Lenacapavir Shows 96% Reduction in Hiv Infections in Purpose 2 Trial
Express News | Gilead - Gilead to Begin Regulatory Filings for Lenacapavir for Prep by End of 2024
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Express News | Gilead Presents Additional Efficacy, Safety and Demographic Data From Purpose 2 Trial at 5TH Hiv Research for Prevention Conference
Gilead Upgraded to Overweight by Wells Fargo, PrEP Launch Cited
Express News | Gilead : Barclays Raises Target Price to $84 From $76
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Wells Fargo Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $100
Gilead Sciences (GILD) Was Upgraded to a Buy Rating at Wells Fargo
Wells Fargo Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts PT to $100 From $78
Express News | Wells Fargo & Co raised the rating of Gilead Sciences from neutral to overweight, with a target price of $100.
Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences' (NASDAQ:GILD) Investors Will Be Pleased With Their Favorable 62% Return Over the Last Five Years
AHF: Global HIV Response Demands Broader Lenacapavir Access
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75
Gilead Sciences Analyst Ratings